The PERLA trial showed consistent OS benefits across various PD-L1 tumor proportion scores, favoring Jemperli over Keytruda.

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Side effects were "generally manageable," according ... For comparison, the KEYNOTE-042 trial, which first established Keytruda monotherapy as the standard of care for PFD-L1-high NSCLC, showed ...

Keytruda is already approved for adjuvant ... with no impact on the ability to complete the surgery and manageable side effects. The company said it plans to file the data with regulators, stating ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded. I would now like ...

Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ETParticipantsSeth Blackley - Chief Executive OfficerJohn ...

Markets rallied strongly this week as investors got a clear outcome in the presidential election and an expected interest rate cut by the Federal Reserve. Is this a relief rally, the continuation of a ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

Drugs like pembrolizumab (Keytruda) can be used in combination with chemotherapy to enhance the immune response against cancer. Radiation Therapy: Radiation therapy uses high-energy rays to target and ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Then there are the health costs. "We don't yet know all the long-term side effects as this is a new trend among non-diabetic ...